PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Procept Biorobotics Corp (PRCT) is not a strong buy at the moment for a beginner investor seeking long-term opportunities. While the company has shown strong revenue growth and gross margin improvements, the stock is currently in a bearish technical trend with hedge funds selling aggressively. Additionally, the lack of recent positive news, weak analyst sentiment shifts, and no significant trading signals from Intellectia Proprietary Trading Signals suggest that this is not an optimal entry point. A hold strategy is recommended until stronger positive catalysts or technical signals emerge.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The RSI is neutral at 38.084, and the MACD is positive but contracting. The stock is trading below the pivot level of 28.495, with key support at 27.21 and resistance at 29.781. Pre-market price is down 1.00%, indicating further weakness.
Gross margin increased to 64.81%, up 2.48% YoY. Analysts from UBS and Morgan Stanley maintain a positive long-term outlook, citing utilization growth and market opportunities.
Hedge funds are aggressively selling, with a 465.92% increase in selling activity last quarter. BofA downgraded the stock to Neutral, citing slowing utilization growth and system placements. EPS dropped 5.00% YoY, and the stock has a 60% probability of declining further in the short term.
In Q3 2025, revenue increased to $83.33M, up 42.76% YoY, and gross margin improved to 64.81%. However, net income remains negative at -$21.41M, with EPS dropping to -0.38, down 5.00% YoY.
Analyst sentiment is mixed. Truist and UBS maintain Buy ratings with price targets of $47 and $62, respectively, citing long-term catalysts. However, BofA downgraded the stock to Neutral with a price target of $38, citing near-term utilization and system placement concerns.
